Myeloid growth factors, version 2.2017

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit RampalVivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, Lenora Pluchino

Research output: Contribution to journalReview articlepeer-review

99 Scopus citations

Abstract

Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimenand patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

Original languageEnglish (US)
Pages (from-to)1520-1541
Number of pages22
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Myeloid growth factors, version 2.2017'. Together they form a unique fingerprint.

Cite this